Rebecca Ellwood, PA
Medical · Albany, NYNPI 1518100403
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $409,707 of the $564,598 with a category attached, or 72.6%. 41 manufacturers reported payments, led by Novo Nordisk at 37.3% of the total. 2025 is the largest year on record at $160,658, 2.3 times the $68,463 reported in 2021. Among medical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,610 payments — averaging $350.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$211K
- Lilly USA, LLC$179K
- Sanofi-aventis U.S. LLC$114K
- Abbott$25K
- Insulet Corporation$20K
- Eli Lilly$6K
- plus $10K from 35 others
What the payments were for
- Consulting fees$9,3472%
- Speaking & faculty fees$409,70773%
- Travel & lodging$120,25921%
- Food & beverage$25,2414%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 340 | $210,760 |
| Lilly USA, LLC | 560 | $179,214 |
| Sanofi-aventis U.S. LLC | 158 | $114,125 |
| Abbott | 99 | $24,534 |
| Insulet Corporation | 97 | $20,026 |
| Eli Lilly | 19 | $6,422 |
| Medtronic | 33 | $3,508 |
| Amgen(2 entities) | 60 | $943 |
| Mannkind Corporation | 34 | $558 |
| AstraZeneca(2 entities) | 33 | $531 |
| Dexcom, Inc. | 25 | $479 |
| Radius Health, Inc. | 18 | $434 |
| Bayer | 27 | $391 |
| AbbVie | 17 | $367 |
| Convatec Inc. | 1 | $240 |
| Sequel Med Tech, LLC | 1 | $214 |
| Ascendis Pharma Endocrinology Inc | 8 | $202 |
| Corcept Therapeutics | 11 | $199 |
| Boehringer Ingelheim | 11 | $173 |
| Pfizer | 7 | $168 |
| Tandem Diabetes Care, Inc. | 4 | $166 |
| IBSA Pharma Inc. | 7 | $135 |
| BETA Bionics, Inc. | 3 | $121 |
| Merck | 6 | $110 |
| Recordati_rare_diseases_inc. | 5 | $91 |
| Amneal Pharmaceuticals LLC | 5 | $90 |
| Ascensia Diabetes Care US Inc. | 2 | $59 |
| Chiesi USA, Inc. | 3 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| Rhythm Pharmaceuticals, Inc. | 1 | $28 |
| Tolmar, Inc. | 2 | $28 |
| BD | 2 | $27 |
| RGH Enterprises LLC | 1 | $19 |
| Bigfoot Biomedical Inc | 1 | $19 |
| Novartis | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| EUSA Pharma (US) LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$130,677
- RYBELSUS$109,907
- TZIELD$108,312
- Ozempic$75,623
- FREESTYLE LIBRE 3$23,205
- LYUMJEV$18,827
- Omnipod$18,553
- MINIMED 770G$1,883
- MINIMED 780G$451
- AQUACEL Ag Advantage Surgical$240
- TWIIST$214
- TEPEZZA$123
- Wegovy$122
- GUARDIAN SENSOR (3)$112
How this compares
$564,598 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $202,592 |
| JardianceEmpagliflozin | 85 | $108,610 |
| MounjaroTirzepatide | 68 | $95,040 |
| TrulicityDulaglutide | 41 | $81,892 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 63 | $66,694 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $63,775 |
| RybelsusSemaglutide | 37 | $49,692 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $47,013 |
| FarxigaDapagliflozin Propanediol | 24 | $29,937 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 20 | $25,457 |
| Repatha SureclickEvolocumab | 17 | $20,174 |
| NovologInsulin Aspart | 54 | $19,678 |
| FiaspInsulin Aspart (Niacinamide) | 15 | $17,832 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $15,639 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $14,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $210,760 | $289,794226 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $179,214 | $188,774149 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Jentadueto | $173 | $127,120108 claims |
| AstraZenecaFarxiga | $531 | $29,93724 claims |
| MerckJanumet | $110 | $8,14614 claims |
| AbbVieSynthroid | $367 | $4,92457 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $90 | $2,682159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.
Other medical in Albany
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
- Kimberly CossaroMassapequa$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.